Tricento Transcatheter Heart Valve for Severe Tricuspid Regurgitation

Montorfano, Matteo; Beneduce, Alessandro; Ancona, Marco; Ancona, Francesco; Sgura, Fabio; Romano, Vittorio; Ferri, Luca; Bellini, Barbara; Khawaja, Saud; Moroni, Francesco; Chieffo, Alaide; Carlino, Mauro; Agricola, Eustachio

doi:10.1016/j.jcin.2019.07.010

Cited by 22 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-implantation planning also includes an accurate CT imaging of the central venous anatomy and size. The prosthesis is currently customized on the basis of patient anatomy of the landing zone, Azygos and hepatic vein confluence [ 34 , 35 ].…”

Section: Dedicated Devicesmentioning

confidence: 99%

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

Altisent

Benetis

Rumbinaitė

et al. 2021

JCM

View full text Add to dashboard Cite

Severe tricuspid regurgitation remains a challenging heart-valve disease to effectively treat with high morbidity and mortality at mid-term. Currently guideline-directed medical treatment is limited to escalating dose of diuretics, and the rationale and timing of open-heart surgery remains controversial. Emerging percutaneous therapies for severe tricuspid regurgitation continue to show promising results in early feasibility studies. However, randomized trial data is lacking. Additionally, many patients are deemed unsuitable for these emerging therapies due to anatomical or imaging constraints. Given the technical simplicity of the bicaval valve implantation (CAVI) technique compared to other transcatheter devices, CAVI is postulated as a suitable alternative for a wide variety of patients affected with severe+ tricuspid regurgitation. In this review we illustrate the current evidence and ongoing uncertainties of CAVI, focusing on the novel CAVI-specific devices.

show abstract

Section: Dedicated Devicesmentioning

confidence: 99%

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

Altisent

Benetis

Rumbinaitė

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…These markers helped the interventional cardiologist substantially in advancing the custom‐made prosthesis to just the right height in the vena cava to ensure an optimal result in the superior and inferior vena cava. In a previous case Montorfano et al used a superior vena cava angiography to identify the SCAJ after insertion of a pigtail through the right jugular vein 7 . We think the demonstrated concept in our case is superior to the previously demonstrated case as it does not need the additional jugular access with consequentially lower risk for bleeding and pneumothorax.…”

Section: Discussionmentioning

confidence: 54%

Fusion imaging guided implantation of a Tricento transcatheter heart valve for severe tricuspid regurgitation

Boeder

Bayer

Dörr

et al. 2021

Cathet Cardio Intervent

View full text Add to dashboard Cite

We report the case of a 64‐year‐old patient with history of chronic kidney disease on dialysis who was repeatedly hospitalized due to hydropic decompensation. Right heart failure with secondary severe tricuspid regurgitation was diagnosed. An interventional approach was recommended due to the heavy calcification of the sinus venosus and the perioperative risk (EuroScore II 3.2%) and taking into account the explicit request of the patient. After analysis of a full‐cycle computed tomography, the patient was eligible for the implantation of the Tricento transcatheter heart valve. The custom‐made prosthesis was implanted successfully using periprocedural transoesophageal guidance supported by fusion imaging that integrates live co‐registration. After implantation of the valve prosthesis, the primary result was excellent. The patient was discharged without further complications shortly after the procedure and her status is being closely monitored.

show abstract

“…16 Another study by Montorfano et al reported complete resolution of peripheral edema at 30 days in 1 patient. 17 Although the Tricento prosthetic valve is promising, the feasibility with current or future pacemakers is unknown, it is not commercially available and it requires custom-made sizing.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous Inferior Vena Cava Valve Implantation May Improve Tricuspid Valve Regurgitation and Cardiac Output: Lessons Learned

Aalaei‐Andabili

Bavry

Choi

et al. 2020

Innovations�(Phila)

View full text Add to dashboard Cite

Tricuspid valve regurgitation (TR) can be associated with poor prognosis. Transcatheter valve technology was adopted to treat the upstream effects of severe TR by placing a transcatheter valve in the inferior vena cava (IVC). In this study, we report off-label transcatheter valve implantation into the stented IVC in patients with severe TR for compassionate use. From September 2018 to February 2020, 6 inoperable patients with severe TR who failed medical treatment underwent percutaneous caval valve implantation (CAVI). Severity of TR was confirmed by intraoperative transesophageal echocardiography. Z-stents (Cook, Inc., Bloomington, IN, USA) were placed in the proximal IVC, and then a transcatheter valve was deployed in the suprahepatic cava without rapid pacing. Six patients, 2 females and 4 males, with a mean ± SD age of 74.7 ± 8.0 years were included. The procedure was successfully performed in all 6 patients (100%) employing a 29-mm SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA, USA) with supranominal volume. No procedural complication was detected. At 30 days, TR improved from severe to trace in 1 patient, to mild-moderate in 3 patients, and 2 patients remained with severe TR. Among patients with improved TR, left ventricular ejection fraction increased from 47.5% ± 18.5% to 55% ± 20.4% ( P = 0.014). No patient had readmission at 30 days. Four patients needed rehospitalization within 6 months. Percutaneous CAVI is feasible and can be considered as a short-term palliative measure in patients with severe TR. CAVI can improve TR and potentially improve cardiac output in selected patients.

show abstract

Tricento Transcatheter Heart Valve for Severe Tricuspid Regurgitation

Cited by 22 publications

References 1 publication

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

Fusion imaging guided implantation of a Tricento transcatheter heart valve for severe tricuspid regurgitation

Percutaneous Inferior Vena Cava Valve Implantation May Improve Tricuspid Valve Regurgitation and Cardiac Output: Lessons Learned

Contact Info

Product

Resources

About